Published in Antimicrob Agents Chemother on January 07, 2013
Variables determining the development of colistin-associated renal impairment. Wien Klin Wochenschr (2015) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis (1999) 5.90
Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother (1999) 4.23
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21
Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis (2009) 3.92
Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect (2005) 3.39
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis (2003) 3.37
Polymyxins revisited. Clin Microbiol Rev (2008) 3.16
High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis (2012) 2.92
Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis (2008) 2.79
Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med (1970) 2.74
Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis (2001) 2.51
Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 2.47
Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care (2003) 2.38
The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med (1962) 2.32
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother (2003) 2.30
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis (2005) 2.10
Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother (2003) 1.90
Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis (2003) 1.89
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents (2009) 1.88
Chronic allograft nephropathy: current concepts and future directions. Transplantation (2006) 1.79
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J (2007) 1.54
Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis (1971) 1.51
Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis (2005) 1.40
Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents (2005) 1.36
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother (2004) 1.34
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents (2009) 1.32
Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol (2011) 1.20
Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents (2006) 1.14
Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents (2009) 1.13
INTRAVENOUS ADMINISTRATION OF SODIUM COLISTIMETHATE. JAMA (1964) 1.08
APNEA WITH INTRAMUSCULAR COLISTIN THERAPY. JAMA (1964) 1.08
Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother (2009) 1.01
Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis (2009) 1.01
Intravenous administration of sodium colistimethate in urinary tract infections. Curr Ther Res Clin Exp (1967) 0.98
THE THERAPEUTIC SUCCESS AND NEPHROTOXICITY OF COLISTIN IN ACUTE AND CHRONIC NEPHROPATHIES WITH IMPAIRED RENAL FUNCTION. Acta Med Scand (1965) 0.97
An unusual case of neuromuscular blockade seen with therapeutic blood levels of colistin methanesulfonate (Coly-Mycin). Am J Med (1966) 0.95
Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant (2007) 0.89
Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc (2007) 0.86
Polymyxin antibiotics: chemical and pharmacokinetic properties. Antibiot Chemother (1971) (1982) 0.82
The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect (2004) 0.79
Certain aspects of drug binding to nonplasma proteins as illustrated by studies with cyclizine, chlorcyclizine, and polymyxin B. Ann N Y Acad Sci (1973) 0.77
Extensive pseudomonal pneumonia ultimately responding to polymyxin therapy. Am Rev Respir Dis (1969) 0.77
Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia. Catheter Cardiovasc Interv (2005) 1.44
Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PLoS One (2011) 1.35
Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis (2013) 1.17
A program for sustained improvement in preventing ventilator associated pneumonia in an intensive care setting. BMC Infect Dis (2012) 1.02
A controlled trial of universal gloving versus contact precautions for preventing the transmission of multidrug-resistant organisms. Am J Infect Control (2007) 1.02
Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome. Transplantation (2010) 1.01
Nosocomial bloodstream infections in Brazilian pediatric patients: microbiology, epidemiology, and clinical features. PLoS One (2013) 0.88
Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates. Microb Drug Resist (2012) 0.83
Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients. BMC Infect Dis (2006) 0.83
Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study. BMC Infect Dis (2007) 0.80
Control of multi-resistant bacteria and ventilator-associated pneumonia: is it possible with changes in antibiotics? Braz J Infect Dis (2007) 0.79
Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes. Transplantation (2014) 0.78
Risk factors for surgical site infection in kidney transplant recipients. Infect Control Hosp Epidemiol (2008) 0.78
High success and low mortality rates with non-invasive ventilation in influenza A H1N1 patients in a tertiary hospital. BMC Res Notes (2011) 0.78
Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol (2003) 0.77
Measuring hand hygiene compliance in a hematology-oncology unit: a comparative study of methodologies. Am J Infect Control (2013) 0.76
Catheter related bloodstream infection (CR-BSI) in ICU patients: making the decision to remove or not to remove the central venous catheter. PLoS One (2012) 0.75
Monitoring for HHV-6 infection after renal transplantation: evaluation of risk factors for sustained viral replication. Transplantation (2013) 0.75
Implementation of an antibiotic prophylaxis protocol in an intensive care unit. Am J Infect Control (2012) 0.75
Contact precautions in the intensive care unit setting: 12 years of surveillance. Am J Infect Control (2012) 0.75
Priority for children in cadaveric kidney sharing: the strategy adopted in Sao Paulo, Brazil. Pediatr Transplant (2004) 0.75
Pregnancy after renal transplantation-setting up a national registry in Brazil. Transplantation (2010) 0.75
The effect of contact precautions on hand hygiene compliance. Am J Infect Control (2012) 0.75
Successful prevention of tracheostomy associated pneumonia in step-down units. Am J Infect Control (2011) 0.75